|
Follow the links below to find summaries of systematic reviews of the evidence for treatments for cystic fibrosis.
Created October 2007
Printer friendly page
| Results 1 to 20 displayed. |
|
1
2
|
| Title: |
Oral calorie supplements for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis affects many organs, including the digestive system. It can lead to food not being absorbed as it should be and so to growth problems. Children with cystic fibrosis need more energy than children without cystic fibrosis, but often have r...
|
| Date: |
Nov 2006
|
| Title: |
Psychological interventions for people with cystic fibrosis and their families
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis is a genetic disorder that damages many of the body's organs and shortens life expectancy. Often people with cystic fibrosis and family members need help to adjust psychologically and emotionally. They also need help to manage the demand...
|
| Date: |
Feb 2008
|
| Title: |
Prophylactic anti-staphylococcal antibiotics for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis blocks the airways with mucus and causes frequent respiratory infections, which may lead to death from breathing failure. People with cystic fibrosis are sometimes given antibiotics regularly in an attempt to prevent infections. However,...
|
| Date: |
May 2003
|
| Title: |
Nebulised anti-pseudomonal antibiotics for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis is an inherited condition which results in abnormal mucus in several parts of the body. The major complication of cystic fibrosis is lung disease. The abnormal mucus in the lung leads to infection with certain bacteria including Pseudomo...
|
| Date: |
May 2003
|
| Title: |
Single versus combination intravenous antibiotic therapy for people with cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis is a serious genetic disease that affects cells in the exocrine glands (sweat glands and others). People with cystic fibrosis have a greater risk of chronic lung infections. They receive antibiotics by injection to treat these. The antib...
|
| Date: |
Feb 2005
|
| Title: |
Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Inflammation contributes to lung damage, which, in the long term, is the most common reason for premature death in cystic fibrosis. In high doses, non-steroidal anti-inflammatory drugs, particularly ibuprofen, may work against inflammation, but in low d...
|
| Date: |
Jun 2007
|
| Title: |
Drug therapies for reducing gastric acidity in people with cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis causes damage to the lungs and to the pancreas. The pancreas produces digestive enzymes which are needed for the body to absorb food. If the pancreas is damaged this can affect how you can absorb food. It can also increase acidity in the...
|
| Date: |
Feb 2003
|
| Title: |
Inhaled bronchodilators for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
We reviewed the effectiveness of inhaled (via metered dose inhaler or nebuliser) bronchodilators in children and adults with cystic fibrosis. Data were collected from 14 trials that looked at either short-acting beta-2 agonists (salbutamol or albuterol,...
|
| Date: |
Aug 2005
|
| Title: |
Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Chronic infection of the airways by Pseudomonas aeruginosa in people with cystic fibrosis is associated with deterioration in respiratory function. Intravenous antibiotics are the standard therapy for pulmonary exacerbations caused by this micro-organis...
|
| Date: |
Aug 2001
|
| Title: |
Nebulised hypertonic saline for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
People with cystic fibrosis produce mucus in their lungs and airways (passages to the lungs) which is hard to clear, leading to infections and airways damage. Chest physiotherapy or drugs (eg deoxyribonuclease) or both are used to try and clear this muc...
|
| Date: |
May 2005
|
| Title: |
Totally implantable vascular access devices for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis (CF) blocks the lungs with mucus, causing frequent infections and lung damage. Antibiotics to treat infections are often needed intravenously (through a vein), but regular injections can damage veins. Another option is a totally implanta...
|
| Date: |
May 2003
|
| Title: |
Dornase alpha for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis (CF) is a genetic disorder which affects the exocrine glands (sweat glands and others). People with CF have a greater risk of chronic lung disease, which can be life-threatening. Lung infections produce thick sputum (phlegm) which can bl...
|
| Date: |
May 2003
|
| Title: |
Omega-3 fatty acids (from fish oils) for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cycles of infection and inflammation are believed to exacerbate lung damage in people with cystic fibrosis. Fish oils are the richest dietary source of omega-3 fatty acids, which studies suggest may be anti-inflammatory and benefit many chronic inflamma...
|
| Date: |
Aug 2007
|
| Title: |
Macrolide antibiotics for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis is characterised by chest infection, particularly by the bacteria, Pseudomonas aeruginosa, which is resistant to nearly all antibiotics that can be taken by mouth. Macrolide antibiotics have no direct killing effect on Pseudomonas aerugi...
|
| Date: |
Feb 2004
|
| Title: |
Vitamin A supplementation for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis can cause certain vitamins, such as vitamin A, to be inadequately absorbed leading to problems caused by vitamin deficiency. Lack of vitamin A (vitamin A deficiency) can cause specific problems such as eye and skin problems. It can also ...
|
| Date: |
Apr 2008
|
| Title: |
Inspiratory muscle training for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
Cystic fibrosis is the most common life-limiting genetic condition in Caucasians. The life-expectancy of those newly diagnosed is increasing. Inspiratory muscle training may improve quality of life, lung function and exercise tolerance in people with cy...
|
| Date: |
Aug 2008
|
| Title: |
Newborn screening for cystic fibrosis
|
| Publisher: |
John Wiley and Sons, Ltd. for The Cochrane Collaboration
|
| Description: |
In people with cystic fibrosis (CF) lung disease and malnutrition occur very early in life and are amenable to early therapy. Newborn screening may therefore improve prognosis of people with CF. This review reports one randomised controlled study which ...
|
| Date: |
Apr 2001
|
| Results 1 to 20 displayed. |
|
1
2
|
|
